TABLE 1.

Characteristics of participants of European ancestry in the CHARGE Consortium Fatty Acids Working Group¹

				Circulating phospholipid fatty acid concentration, % of total fatty acids2
Cohort	n	Age, y	Women, %	trans-16:1n–7	total trans-18:1	cis/trans-18:2	trans/cis-18:2	trans/trans-18:2
CARDIA	1507	45.8 ± 3.4	53.3	0.056 ± 0.028	1.489 ± 0.632	0.048 ± 0.021	0.133 ± 0.053	0.030 ± 0.021
CHS	2404	75.0 ± 5.1	61.6	0.190 ± 0.05	2.010 ± 0.71	0.080 ± 0.02	0.130 ± 0.05	0.050 ± 0.04
GOLDN	793	48.3 ± 15.9	50.4	0.073 ± 0.029	1.442 ± 0.424	0.086 ± 0.023	0.097 ± 0.032	0.043 ± 0.024
HPFS	1295	64.3 ± 8.6	0	0.137 ± 0.045	1.498 ± 0.639	0.116 ± 0.049	0.085 ± 0.043	0.014 ± 0.018
MESA	707	61.6 ± 10.4	61.6	0.064 ± 0.027	1.493 ± 0.675	0.062 ± 0.021	0.135 ± 0.059	0.038 ± 0.023
NHS	655	59.9 ± 6.5	100	0.152 ± 0.045	1.619 ± 0.711	0.176 ± 0.064	0.135 ± 0.055	0.087 ± 0.059
WGHS	652	54.4 ± 6.5	100	0.055 ± 0.026	1.791 ± 0.527	0.089 ± 0.023	0.098 ± 0.048	0.033 ± 0.012

¹Values are means ± SDs unless otherwise indicated. CARDIA, Coronary Artery Risk Development in Young Adults Study; CHARGE, Cohorts for Heart and Aging Research in Genomic Epidemiology; CHS, Cardiovascular Health Study; GOLDN, Genetics of Lipid-Lowering Drugs and Diet Network; HPFS, Health Professionals Follow-Up Study; MESA, Multi-Ethnic Study of Atherosclerosis; NHS, Nurses’ Health Study; WGHS, Women's Genome Health Study.

²Fatty acids were measured in erythrocyte membrane phospholipids (GOLDN, HPFS, and NHS) or plasma phospholipids (CARDIA, CHS, MESA, and WGHS).